New combo targets genetic weakness in advanced breast cancer
NCT ID NCT04524000
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tests a combination of two drugs (alpelisib and fulvestrant) in 24 Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that worsened after prior hormone therapy. The goal is to see if the combination is safe and can shrink tumors. Participants take both drugs as pills or shots, and the study tracks side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Nagoya, Aichi-ken, 464 8681, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4678602, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Isehara, Kanagawa, 259-1193, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 241-8515, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 9808574, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5400006, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
Suita, Osaka, 565-0871, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 135-8550, Japan
-
Novartis Investigative Site
Meguro-ku, Tokyo, 152-8902, Japan
-
Novartis Investigative Site
Kumamoto, 860-8556, Japan
-
Novartis Investigative Site
Niigata, 951-8566, Japan
Conditions
Explore the condition pages connected to this study.